THU0687 FEASIBILITY AND VALIDITY OF PROMIS ® GLOBAL HEALTH SHORT FORM (PROMIS10) IN OUTPATIENTS WITH SLE
Background: Routine measurement of patient reported outcomes (PROs) is a priority for improving quality of care and outcomes in chronic rheumatic conditions including systemic lupus erythematosus (SLE) . Measuring PROs at the point of care requires validated instruments with minimal responder burden. PROMIS10 is a 10 question universal (non-disease specific) PRO instrument measuring physical and mental health domains with T-scores normalized to the general population (mean score =50). The feasibility and validity of PROMIS10 have not been demonstrated in SLE. Objectives: To evaluate: 1) feasibility and 2) validity of PROMIS10 in outpatients with SLE. Methods: Adults meeting 1997 ACR SLE classification criteria were recruited from an SLE Center of Excellence. Subjects completed SF-36, LupusQoL-US, selected PROMIS Computerized Adaptive Tests (CATs), and PROMIS10. Construct validity was evaluated using Spearman's correlations comparing PROMIS10 physical and mental health scores with PROMIS CATs and legacy instruments. Test-retest reliability was evaluated in subjects reporting stable SLE activity at 2 assessments a week apart with intraclass correlation coefficients (ICCs). Focus groups of participants evaluated the relevance and utility of PROMIS10. Background: ANCA-associated vasculitis (AAV) is a potentially life threatening condition requiring careful monitoring and balancing of treatment options to minimize morbidity and mortality. Objectives: To investigate the influence of baseline disease characteristics and induction therapy on the disease course and outcome in ANCA-associated vasculitis. Methods: Single centre longitudinal cohort study of all adult patients with an EMEA algorithm based diagnosis of AAV followed up to August 2016. Clinical data including disease activity (BVAS), ANCA type and level, treatment, relapses (BVAS >3) and organ damage (VDI) and other complications (e.g. infections) during the disease course were recorded. Predictors for ESRD, death, cancer and damage accrual were analysed by multivariate logistic regression presented as Odds Ratios (OR). Results: A total of 63 patients (59% male) (mean age at diagnosis 57 years, 59% with GPA, 24% MPA and 16% EGPA) were included. Fluorescence ANCA was positive in 92%, while 47% had MPO-ANCA and 43% PR3-ANCA. Induction therapy included corticosteroids (92%), Cyclophosphamide (57%), Rituximab (35%) and Plasmapheresis (6%). During 46 months of follow-up 34 patients (54%) experienced 71 relapses (rate 2.5/100 months) and 55 serious complications occurred (rate 2/100 months). Mean VDI at last follow-up was 2.1 with only 11 patients (17.4%) not developing organ damage. Averaged BVAS correlated with last VDI scores (Rs 0.25,p=0.012). Overall, 4 patients (6.3%) died, 19 (27%) developed renal insufficiency of which 2 (3.1%) required chronic dialysis, while 6 (9.5%) developed a new cancer. Age was an independent predictor (OR 1.09, p=0.05) for patient survival (95% and 91% at 1 and 5 years), but no effect was seen for baseline BVAS, gender, AAV or ANCA subtype (all p>0.1). Conclusions: While current treatment reduces the risk of death, AAV is still associated with a high rate of disease relapse, organ damage accrual and serious complications. Background: According to previous studies, serum amyloid A (SAA) is involved in the pathophysiology of several conditions including inflammatory arthritis and psoriasis. Recent evidence suggests its valuable role in monitoring disease activity in Rheumatoid Arthritis, but its role is yet to be determined in Psoriatic Arthritis (PsA). Objectives: To study the association between SAA levels and its variation with other biomarkers and disease activity/functional parameters in a cohort of PsA patients under biologic therapy. Methods: Observational retrospective study was conducted including PsA patients (according to CASPAR criteria) followed at our Rheumatology department with at least one measurement of SAA levels from January 2015 until December 2016. Demographic and clinical data were obtained by consulting the national database (Reuma.pt). The disease activity/functional scores from at least one visit and corresponding measurements of SAA, ESR and CRP levels were collected. The difference ( ) between 2 evaluations separated by a median time of 6 months [6-18] was calculated for all variables. Agreement between dichotomized biomarkers was calculated using kappa coefficients. Correlations were studied using Pearson and Spearman coefficient analysis. Significance level was set as 0.05. Results: 53 PsA patients were included. 31 (59%) patients were females with a mean (SD) age of 50 (11.2) years and a median disease duration of 9 years . 28% had axial involvement, 34% peripheral involvement and 38% had both types. All patients were under biologic DMARD. 100 SAA measurements were collected. Median SAA and ESR levels were significantly superior in female patients (23 vs 6mm/1sth and 8.6 vs 4.4mg/L, respectively, p<0.05) and only ESR levels correlated with age (r=0.20, p=0.05). The three biomarkers showed a weak association with serum creatinine levels, with greater correlation for SAA (r=0.46, p<0.001). SAA levels had a stronger correlation with CRP (r=0.75, p<0.001) than with ESR levels (r=0.26, p<0.01). SAA and CRP (dichotomized as negative/positive) had a greater level of agreement (κ=0.40) compared to ESR (κ=0.26 and κ=0.32, respectively) . No significant correlations were found between the biomarkers and the tender/swollen joint count or the pain/global disease activity VAS. SAA levels correlated with ASDAS CRP (r=0.43, p<0.001) and weakly with ASDAS ESR and DAS28 CRP (r=0.20 and r=0.24, respectively, p<0.05) . Only ESR had a significant weak correlations with BASDAI, MASES and SPARCC scores (r=0.25, r=0.21, r=0.35; p<0.05) . All the biomarkers had weak correlations with BASFI and HAQ scores. SAA levels had a weak correlation with CRP (r=0.32, p=0.03; n=47) and no significant association was found with ESR. SAA correlated significantly with ASDAS CRP and BASMI (r=0.32, r=0.39; p<0.05) . Conclusions: This study showed that SAA levels and its variation had a significant correlation with CRP levels and its variation, respectively. Significant association with ASDAS CRP variations suggests that serial measurements of SAA may represent an additional marker for monitoring disease activity over time in PsA patients. Background: Quantitating the degree of inflammation has become essential to tailor the treatment strategy of various rheumatic diseases. Traditionally used measures to assess disease activity and treatment response in spondyloarthritis (SpA) are ESR, CRP and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS). Serum amyloid A (SAA) is an acute-phase reactant predominantly synthesized in the liver by hepatocytes in response to proinflammatory cytokines. Some studies have shown that SAA can be a valuable indicator of disease activity, damage and functional impairment, however it has not been extensively used in clinical practice. Objectives: To investigate if SAA levels have better correlation with conventional assessments used to monitor anti-tumor necrosis factorα (anti-TNF) treatment in SpA than CRP and ESR. Methods: Prospective study, including SpA patients under anti-TNFα treatment at a Rheumatology Department of a Portuguese Universitary Hospital. The following parameters were collected and registered in two different evaluations 6 months apart from each other: SAA, CRP and ESR levels, BASDAI, ASDAS-PCR, ASDAS-VS, BASFI, BASMI, swollen and tender joints counts (SJC and TJC), MASES, SPARCC, and patient global assessment (PtGA), physician global assessment (PGA), total back pain (TBP), nocturnal back pain (NBP) measured in a visual analogue scale (VAS). The variation of each parameter was calculated as the difference between the levels registered at each evaluation (baseline and 6 months) and presented as (parameter). We compared the correlation between SAA, CRP and ESR levels with BASDAI, ASDAS-PCR, ASDAS-VS, BASFI, BASMI, SJC, TJC, MASES, SPARCC, PtGA-VAS, PGA-VAS, TBP-VAS, NBP-VAS. The statistical analysis was performed using SPSS 21.0 software, and p<0.05 was taken to indicate statistical significance. Correlation was calculated using the Spearman rank correlation (r). Results: 89 patients were included, 58.4% (n=52) were male. On baseline the median age was 44.0 years (range 21.0-74.6) and median disease duration was 18.8 years (2-51.6). SAA was moderately correlated with CRP (r=0.65,
